Publikationer – Gustav Ullenhag

Publikationer i DiVA

Publikationer i PubMed


Ett urval av våra artiklar:

  1. Irenaeus S, Maleka A, Wenthe J, Svensson E, Krause J, Sundin A, Ahlström H, Tötterman T, Loskog A och Ullenhag G. Immunostimulatory AdCD40L gene therapy combined with local radiation and low-dose cyclophosphamide in patients with advanced malignant melanoma. Accepterad för publicering i Oncotarget, juni 2017.
     
  2. Loskog A*, Maleka A*, Mangsbo S, Svensson E, Lundberg C, Nilsson A, Krause J, Agnarsdóttir M, Sundin A, Ahlström H, Tötterman TH#, Ullenhag G#. Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients. Br J Cancer. 2016, 114(8):872-80. * delat förstaförfattarskap, # delat sistaförfattarskap.
     
  3. Maleka A, Enblad G, Sjörs G, Lindqvist A, Ullenhag GJ. Treatment of metastatic malignant melanoma with vemurafenib during pregnancy. J Clin Oncol. 2013, (11):e192-3.
     
  4. Staff C, Magnusson CG, Hojjat-Farsangi M, Mosolits S, Liljefors M, Frödin JE, Wahrén B, Mellstedt H, Ullenhag GJ. Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein. J Clin Immunol. 2012, 32(4):855-65.
     
  5. Ullenhag GJ*, Sadeghi AM*, Carlsson B, Ahlström H, Mosavi F, Wagenius G, Tötterman TH. Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy. Cancer Immunol Immunother. 2012, 61(5):725-32. * GJU och AMS bidrog till lika del i publikationen.
     
  6. Ullenhag GJ, Mukherjee A, Watson NF, Al-Attar AH, Scholefield JH, Durrant LG. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res. 2007, 13(17):5070-5.
     
  7. Ullenhag GJ, Spendlove I, Watson NF, Indar AA, Dube M, Robins RA, Maxwell-Armstrong C, Scholefield JH, Durrant LG. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin Cancer Res. 2006, 12(24):7389-96.
     
  8. Ullenhag GJ, Frödin JE, Jeddi-Tehrani M, Strigård K, Eriksson E, Samanci A, Choudhury A, Nilsson B, Rossmann ED, Mosolits S, Mellstedt H. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin Cancer Res. 2004, 10(10):3273-81. (Utsedd till Feature Article").
     
  9. Ullenhag GJ, Frödin JE, Mosolits S, Kiaii S, Hassan M, Bonnet MC, Moingeon P, Mellstedt H, Rabbani H. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response. Clin Cancer Res. 2003, 9(7):2447-56.
     
  10. Ullenhag GJ, Frödin JE, Strigård K, Mellstedt H, Magnusson CG. Induction of IgG subclass responses in colorectal carcinoma patients vaccinated with recombinant carcinoembryonic antigen. Cancer Res. 2002, 62(5):1364-9. (En av de mest citerade cancerartiklarna överhuvudtaget på kort sikt enligt citeringsindex.)